CN112867489A - Sarm1抑制剂 - Google Patents

Sarm1抑制剂 Download PDF

Info

Publication number
CN112867489A
CN112867489A CN201980052440.2A CN201980052440A CN112867489A CN 112867489 A CN112867489 A CN 112867489A CN 201980052440 A CN201980052440 A CN 201980052440A CN 112867489 A CN112867489 A CN 112867489A
Authority
CN
China
Prior art keywords
compound
aliphatic
formula
sarm1
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980052440.2A
Other languages
English (en)
Chinese (zh)
Inventor
R·O·休斯
R·德夫拉吉
T·博萨纳
R·A·杰里斯-派克
A·S·布雷利
J·本特利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Disarm Therapeutics Inc
Original Assignee
Disarm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disarm Therapeutics Inc filed Critical Disarm Therapeutics Inc
Priority to CN202510537996.8A priority Critical patent/CN120398784A/zh
Publication of CN112867489A publication Critical patent/CN112867489A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201980052440.2A 2018-06-07 2019-06-06 Sarm1抑制剂 Pending CN112867489A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510537996.8A CN120398784A (zh) 2018-06-07 2019-06-06 Sarm1抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682054P 2018-06-07 2018-06-07
US62/682,054 2018-06-07
PCT/US2019/035846 WO2019236890A1 (en) 2018-06-07 2019-06-06 Inhibitors of sarm1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510537996.8A Division CN120398784A (zh) 2018-06-07 2019-06-06 Sarm1抑制剂

Publications (1)

Publication Number Publication Date
CN112867489A true CN112867489A (zh) 2021-05-28

Family

ID=68770700

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980052440.2A Pending CN112867489A (zh) 2018-06-07 2019-06-06 Sarm1抑制剂
CN202510537996.8A Pending CN120398784A (zh) 2018-06-07 2019-06-06 Sarm1抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510537996.8A Pending CN120398784A (zh) 2018-06-07 2019-06-06 Sarm1抑制剂

Country Status (6)

Country Link
US (1) US12624026B2 (cg-RX-API-DMAC7.html)
EP (1) EP3801503A4 (cg-RX-API-DMAC7.html)
JP (1) JP7481329B2 (cg-RX-API-DMAC7.html)
CN (2) CN112867489A (cg-RX-API-DMAC7.html)
MA (1) MA52812A (cg-RX-API-DMAC7.html)
WO (1) WO2019236890A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023193809A1 (zh) * 2022-04-08 2023-10-12 深圳众格生物科技有限公司 Sarm1抑制剂化合物、包含其的药物组合物及其制备方法和用途

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
CA3102645A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
CN112955150A (zh) * 2018-10-19 2021-06-11 达萨玛治疗公司 与nad+或nad+前体组合的sarm1抑制剂
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
US12624025B2 (en) * 2019-06-06 2026-05-12 Disarm Therapeutics, Inc. Inhibitors of SARM1
JP7319395B2 (ja) 2019-06-14 2023-08-01 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
WO2021050913A1 (en) 2019-09-12 2021-03-18 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2021108602A1 (en) * 2019-11-26 2021-06-03 Disarm Therapeutics, Inc. Methods and compositions for neuroprotection
EP4083037A4 (en) * 2019-12-26 2024-01-24 Yonsei University, University-Industry Foundation(UIF). Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or tau protein-associated diseases containing same
AU2021206651B2 (en) * 2020-01-07 2024-02-22 Disarm Therapeutics, Inc. Inhibitors of SARM1
CA3174321A1 (en) 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Indazole derivatives as inhibitors of sarm1
WO2021207308A1 (en) 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Condensed pyrazole derivatives as inhibitors of sarm1
EP4192828A1 (en) 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
TW202334117A (zh) 2020-08-24 2023-09-01 美商達薩瑪治療公司 Sarm1之抑制劑
WO2022060812A1 (en) * 2020-09-16 2022-03-24 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
CN117797146A (zh) * 2020-11-12 2024-04-02 科辉智药生物科技(无锡)有限公司 Sarm1酶活性抑制剂及其在神经退行性疾病中的应用
CA3200439A1 (en) * 2020-12-08 2022-06-16 Disarm Therapeutics, Inc. Benzopyrazole inhibitors of sarm1
KR20240041987A (ko) 2021-07-28 2024-04-01 누라 바이오, 인크. Sarm1 억제제로서 치환된 피리딘 유도체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040039037A1 (en) * 2002-06-04 2004-02-26 Weijian Zhang Heterocyclic compounds and uses thereof
CN1658881A (zh) * 2002-06-12 2005-08-24 坎莫森特里克斯公司 抗炎组合物及其使用方法
US20060217390A1 (en) * 2005-02-24 2006-09-28 Esmir Gunic Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus
CN113164508A (zh) * 2018-12-19 2021-07-23 达萨玛治疗公司 与神经保护剂组合的sarm1抑制剂

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA847926B (en) 1983-10-17 1986-05-28 Lilly Co Eli 3-bicyclicpyridinium-methyl cephalosporins
EP0187456A1 (en) 1984-11-29 1986-07-16 Ici Pharma Cephalosporin derivatives
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
CA2443918C (en) 2001-04-11 2012-06-05 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents containing rho kinase inhibitors
JP2006516603A (ja) 2003-01-27 2006-07-06 ファイザー・プロダクツ・インク イソチアゾール誘導体
WO2005082001A2 (en) 2004-02-20 2005-09-09 The Scripps Research Institute Advanced isothiazole based protein kinase inhibitors
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
US7557103B2 (en) 2005-04-05 2009-07-07 Eli Lilly And Company Imidazopyridazine compounds
WO2006133417A1 (en) * 2005-06-07 2006-12-14 Valeant Pharmaceuticals International Phenylamino isothiazole carboxamidines as mek inhibitors
WO2008118626A2 (en) 2007-03-08 2008-10-02 Burnham Institute For Medical Research Inhibitors of jnk and methods for identifying inhibitors of jnk
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US8067452B2 (en) 2007-06-21 2011-11-29 Valeant Pharmaceuticals International 3-hydroxyisothiazole-4-carboxamidine derivatives as CHK2 inhibitors
US20100324049A1 (en) 2007-09-27 2010-12-23 Makoto Ando Diaryl ketimine derivative having antagonism against melanin-concentrating hormone receptor
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Chk−1阻害剤としての6置換2−ヘテロシクリルアミノピラジン化合物
WO2011019678A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Isothiozoles for treating conditions of the eye
CA2780922A1 (en) 2010-02-11 2011-08-18 OSI Pharmaceuticals, LLC 7-aminofuropyridine derivatives
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
WO2012178022A2 (en) 2011-06-24 2012-12-27 University Of Massachusetts Therapeutic applications targeting sarm1
GB201310460D0 (en) 2013-06-12 2013-07-24 Lytix Biopharma As Compounds
WO2018011628A1 (en) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EP4091622A1 (en) 2016-08-16 2022-11-23 Henry Ford Health System Compositions for the treatment of chemotherapy-induced neuropathic pain
EP3515426A1 (en) 2016-09-24 2019-07-31 Washington University INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF
TWI763722B (zh) 2016-10-14 2022-05-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
IL251949A0 (en) * 2017-04-26 2017-07-31 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Small organic molecules for use in the treatment of neuro-inflammatory diseases
CA3102645A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
US12624025B2 (en) 2019-06-06 2026-05-12 Disarm Therapeutics, Inc. Inhibitors of SARM1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040039037A1 (en) * 2002-06-04 2004-02-26 Weijian Zhang Heterocyclic compounds and uses thereof
CN1658881A (zh) * 2002-06-12 2005-08-24 坎莫森特里克斯公司 抗炎组合物及其使用方法
US20060217390A1 (en) * 2005-02-24 2006-09-28 Esmir Gunic Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus
CN113164508A (zh) * 2018-12-19 2021-07-23 达萨玛治疗公司 与神经保护剂组合的sarm1抑制剂

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AHMAD BASHEER ET AL: "A Rich Array of Reactions of Cyanomonothiocarbonylmalonamides RNHCSCH(CN)CONHR′and Their Thioenols RNHC(SH)dC(CN)CONHR′1" *
CHAMAKURA V. N. S. ET AL: "Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors" *
LAUREN J WALKER ET AL: "MAPK signaling promotes axonal degeneration by speeding the turnover of the axonal maintenance factor NMNAT2" *
SHAOYONG KE: "Convenient Structural Diversity-Guided Synthesis of Functionalized Sulfur-Containing Heterocycles via α-Substituted Cyanoacetamides" *
SHUNQI YAN ET AL: "Isothiazoles as active-site inhibitors of HCV NS5B polymerase" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023193809A1 (zh) * 2022-04-08 2023-10-12 深圳众格生物科技有限公司 Sarm1抑制剂化合物、包含其的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
EP3801503A1 (en) 2021-04-14
JP2021527126A (ja) 2021-10-11
CN120398784A (zh) 2025-08-01
CA3108669A1 (en) 2019-12-12
MA52812A (fr) 2021-04-14
EP3801503A4 (en) 2021-12-08
WO2019236890A1 (en) 2019-12-12
US20210261537A1 (en) 2021-08-26
JP7481329B2 (ja) 2024-05-10
US12624026B2 (en) 2026-05-12

Similar Documents

Publication Publication Date Title
CN112839647B (zh) Sarm1抑制剂
CN112839648B (zh) Sarm1抑制剂
CN113950326B (zh) Sarm1抑制剂
Hu et al. Cellular senescence in cardiovascular diseases: a systematic review
JP7481329B2 (ja) Sarm1阻害剤
D'Onofrio et al. MiR-27b attenuates mitochondrial oxidative stress and inflammation in endothelial cells
CN113164508B (zh) 与神经保护剂组合的sarm1抑制剂
He et al. A positive autoregulatory loop of Jak-STAT signaling controls the onset of astrogliogenesis
CN115916764B (zh) 作为sarm1抑制剂的吲唑衍生物
US9662314B2 (en) Compounds and methods for the treatment of muscular disease, and related screening methods
KR102359994B1 (ko) 급성 중추 신경계 손상 질병에 대한 헥소키나제2 특이적 억제제의 응용
US20220090086A1 (en) Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders
Kang et al. Knockdown of TRIM22 relieves oxygen–glucose deprivation/reoxygenation-induced apoptosis and inflammation through inhibition of NF-κB/NLRP3 axis
KR20250006359A (ko) Sirna 생체 이용률을 개선하기 위한 galnac 조성물
Guo et al. Prolonged retention of albumin nanoparticles alleviates renal ischemia-reperfusion injury through targeted pyroptosis
Hu et al. Suppression of Nestin reveals a critical role for p38-EGFR pathway in neural progenitor cell proliferation
KR101268478B1 (ko) Dkk3 발현 또는 활성 억제제를 함유하는 암 예방 및 치료용 조성물
KR101384360B1 (ko) Scf 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
US20230159935A1 (en) CIRCULAR BIFUNCTIONAL APTAMERS AND TRIFUNCTIONAL APTAMERS TARGETING Tau
Sun et al. Antihypoxic effect of miR-24 in SH-SY5Y cells under hypoxia via downregulating expression of neurocan
JP5697229B2 (ja) 血管新生阻害剤
CN106619595A (zh) 包含2,5‑二羟基苯磺酸的用于促进神经细胞中髓鞘再生的组合物及其用途
TW202615058A (zh) 失養強直性肌肉蛋白質激酶(dmpk)irna組成物及其使用方法
WO2013036031A2 (ko) microRNA486 발현 억제제를 유효성분으로 포함하는 신경계 질환 예방 및 치료용 약학적 조성물
McAvoy Non-cell Autonomous Toxicity in Motor Neuron Disease: Evidence and Mechanisms of Astrocyte-Driven Neurotoxicity in FUS-ALS

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination